




JANE-2 Joint Action on Networks of Expertise on Cancer EU funded Joint Action

**Building new Networks of Expertise (NoEs) in oncology:
An Ambitious Vision for Tackling Healthcare at EU level**

3rd Newsletter-June 2026


The EU Joint Action on Networks of Expertise on cancer - JANE-2 (EU4H-2023-JA-3-IBA- GA 101183265) (<https://jane-2.eu/>), launched on November 1st 2024, involves **133 organizations from 29 European countries**. It is coordinated by Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Italy, and co-funded by the European Union with **40.5 million EUR**.

JANE-2 aims at building seven Networks of Expertise (NoEs) in the area of oncology that will transform the way cancer care will be delivered at EU level. By the end of JANE-2, the NoEs will be inclusive, sustainable, and ready to collaborate with other European oncology initiatives. To enhance collaboration across Europe, JANE-2 has launched a **Restricted Network entitled EU Health Networks – Synergies and Challenges**, hosted on the European Commission’s **Health Policy Platform**, with the support of DG SANTE bringing together **16 cancer-related Joint Actions, EU projects and ERNs** (EChoS, JARDIN, TEHDAS-2, CAN.HEAL, eCAN Plus, EUCanScreen, JA PreventNCD, CCI4EU, EURACAN, ERN-PaedCAN, ERN-EuroBloodNet, ERN GENTURIS, EUnetCCC, JA Cancer Watch, JA Hope4Kids and JANE-2).



The aim of the HPP Restricted Network is to jointly discuss the synergies and to tackle challenges experienced by joint actions, EU projects and ERNs, while developing new EU Health Networks. The focus is on ensuring the long-term **sustainability** of these networks in terms of financial, institutional, operational and political aspects.

To this end, **subgroups** have been created on **nine thematic areas** to address synergies and overlaps across the members of the **HPP Restricted Network- EU Health Networks: Synergies and Challenges**.



During the past six months (**November 2025 - April 2026**), significant progress was made towards the objectives of the project. The developments per Work Package/NoE, so far, are described as follows:

WP1 Project Management and Coordination

Sustainability has become the thread running through the Coordination Team's work this past semester.

Three well-attended gatherings of the Restricted Network hosted by JANE-2 on the EC Health Policy Platform (HPP) - EU Health Networks: Synergies and Challenges - brought together Coordinators of Joint Actions, EU projects and European Reference Networks active in cancer, including two newly launched JAs. The focus of the conversations was how to secure the long-term sustainability of EU health networks on cancer. A joint statement is now under preparation to capture the shared challenges across all participating initiatives.

The Coordination Team has also contributed to a series of other collaborative moments. At the EUnetCCC Kick-Off meeting in Paris in November 2025, the Team led two sessions on the strategic role of EU health networks in shaping coordinated, impactful responses to Europe's cancer challenges. JANE-2 participated in two European Parliament events, including the ECHoS consortium meeting, Bringing the cancer mission hubs to the heart of Europe, and the CCI4EU Policy Forum on addressing inequalities in cancer care through Europe-wide networks and infrastructures.

More recently, the Team contributed to the high-level EUnetCCC high-level policy event Strengthening Comprehensive Cancer Care in Europe held in Nicosia under the auspices of the Cyprus Presidency of the Council of the EU, where sustainability again stood at the centre of debate.

JANE-2 collaboration with the EC has continued steadily, including active participation in two meetings of the Subgroup on Cancer under the Public Health Expert Group Board, providing updates on HPP Restricted Network activities and on progress across JANE-2's seven NoEs.

The second online brainstorming meeting of JANE-2's Policy Board took place in January 2026. This new body brings together Competent Authorities from the 29 participating countries, alongside representatives of

national health ministries and other decision makers to identify challenges and set priorities for the seven NoEs from a Member State perspective.

WP2 Dissemination and Communication

Over M13–M18, WP2 strengthened JANE-2’s communication and dissemination activities, focusing on a more structured, consistent and data-driven social media strategy.



LinkedIn & Bluesky: A clear framework was implemented around three content lines: WP storytelling posts, cancer awareness days aligned with the European cancer calendar, and project updates on JANE-2 milestones and deliverables. This has improved publication rhythm, alignment with the Networks of Expertise (NoEs), and coordination across partners.

Instagram: WP2 is implementing a renewed Instagram strategy aimed at the general public, broadening JANE-2’s reach beyond professional and policy audiences. Content is organized around: About JANE-2, News from JANE-2, Cancer Awareness Days, and People behind the project.

Monthly Campaigns: Targeted LinkedIn campaigns were carried out in Italy, Portugal, Greece and Denmark to attract audiences in priority countries. Recent data from March–April 2026 confirms consistent visibility and interaction, especially for cancer awareness days and expert-driven content.

At this stage, the project has reached a total community of 3,940 followers: 3,721 on LinkedIn (119.1% increase since November 2025), 153 on Bluesky and 66 on Instagram. JANE-2 maintains a regular rhythm with an average of 13 posts per month on LinkedIn, 13 on Bluesky and 10 on Instagram.

WP2 team also focused on planning additional dissemination and communication actions including a series of podcasts and webinars addressing targeted audiences (policy makers, health professionals, citizens).

Podcasts: WP2 is developing JANE-2 Talks, a professional podcast series, as a new dissemination format to bring the project closer to wider European audiences. Its visual identity, format and episode structure have already been defined, creating a consistent framework for upcoming recordings.

Webinars: The concept is a series of conversations giving voice to researchers and clinicians to ensure that innovation truly reaches those who need it most. The webinars are addressed to a) citizens with an active interest in cancer and b) experts outside the context of JANE-2. Each webinar has a topic focused on a NoE and the first webinar entitled “Translational challenges in integrating innovative omics into practice” will take place on 2nd July 2026.

Furthermore, the **JANE-2 website** remains the basic channel for the dissemination and communication of the Joint Action’s activities and its content is continuously revised and updated. Importantly, the Patient Information Corner is being enriched with significant material and tools from the NoEs (ELSI Navigator from NoE on Omics, Physical Activity Guidebook from the NoE on Personalized Primary & Secondary Cancer Prevention).

WP3 Evaluation

Evaluation Update: What's New in WP3

Keeping track of progress is at the heart of WP3's work — and the past months have been busy.

Updating and improving our monitoring tools

After the first project year, the team reviewed all Key Performance Indicators (KPIs) to ensure they still reflect where the project is heading. A dedicated workshop helped partners understand the revision process and contribute meaningfully to it. Alongside this, the monitoring system has been strengthened with two new features: one to flag delayed indicators and record reasons, and one to alert when results fall below agreed thresholds. The updated KPIs are now being rolled out, and the internal partner dashboard will be updated accordingly.

Hearing from partners

A satisfaction survey was sent to all JANE-2 partners on May 22, 2026. It covers multiple aspects of the project experience while keeping things concise for respondents. Results will be analysed over the summer and reported later this year.

Supporting the Networks of Expertise — preparing for the future

A key priority for WP3 is ensuring that each Network of Expertise (NoE) is well-equipped to monitor and evaluate their own work once JANE-2 concludes. WP3 is therefore co-developing tailored evaluation frameworks with each NoE throughout the duration of JANE-2. A scoping review on evaluation and self-monitoring methods in professional and health networks has been conducted to inform this work and has now been submitted for peer review — with the evidence gathered directly feeding into our co-development of the frameworks with each NoE.

WP4 Sustainability

WP4 activities during this period have primarily focused on the dissemination of the JANE-2 Needs Assessment survey and the preparation of the first milestone of this WP with the results of this analysis, both of which constitute key steps in shaping the future direction of the project.

A coordinated dissemination strategy was implemented to maximize participation in the Needs Assessment across stakeholder groups. This included targeted outreach through the Networks of Expertise (NoEs), engagement of WP leaders and partners, and the use of existing professional networks to ensure broad visibility. These efforts were instrumental in gathering a diverse range of inputs, reflecting current practices, challenges, and priorities in cancer-related expertise at national and European levels.

The main objective of this dissemination effort was not only to ensure a robust response rate, but also to promote ownership and active engagement of stakeholders in the co-creation process underpinning JANE-2. By encouraging contributions from clinicians, researchers, and policymakers, the Needs Assessment has laid a strong foundation for evidence-informed decision-making within the project.

In parallel, significant work has been dedicated to the preparation of the corresponding milestone, focusing on the analysis, consolidation, and clear presentation of the results. Particular attention has been given to translating findings into actionable insights that can guide the development of recommendations and future actions within each Network of Expertise.

The results of the Needs Assessment will directly support next steps in the activity of WP4, and contribute to ensuring that future activities of the NoEs will be responsive to identified needs and gaps. This will be

essential to guarantee that the services designed are relevant, targeted, and capable of delivering tangible value, thereby strengthening the impact, coherence, and long-term sustainability of the NoEs.



WP5 NoE on Complex and Poor Prognosis Cancer

Over the past months, WP5 has continued to advance the work on complex and poor-prognosis cancers across Europe. Efforts have focused on strengthening collaboration, developing frameworks, and creating a solid foundation for future activities.

The Networks of Expertise (NoEs) for Pancreatic and Lung cancers are now fully underway, marking an important milestone. The Pancreatic Cancer NoE has already held multiple meetings and is steadily building a multidisciplinary platform to enhance care quality, foster research, and strengthen collaboration across national and regional networks. An onsite meeting is also being planned for autumn to further support this work. The Lung Cancer NoE was launched in late spring and builds on existing European initiatives to improve outcomes.

Across WP5 tasks, significant progress has been made in several core areas:

Clinical guidelines and care pathways: Work is ongoing to review and harmonise guidelines and quality standards, helping to reduce variation in care across countries

Research and innovation: Mapping of advanced technologies and planning of pilot studies are underway to support the integration of innovation into clinical practice.

Education and training: A first framework for a harmonised core curriculum has been developed, with further refinement planned together with project partners.

Important groundwork has also been laid in areas that will support long-term impact. Activities include the development of policy reviews, stakeholder engagement strategies, and governance structures that enable effective collaboration and decision-making.

At the same time, work on evaluation and sustainability is progressing, with a focus on ensuring that WP5 outcomes can be scaled up and integrated into future European initiatives.



WP6 NoE on Palliative Care

During months 13–18, WP6 focused on building a shared European knowledge base for integrating timely, needs-based palliative care into cancer care. Across the four tasks, complementary mapping activities were aligned to capture how palliative care is organised, delivered, taught and monitored, as well as how PROMs and patient-centred pathways are used in practice. Together, this work will provide a broad picture of system-level structures, clinical practice and implementation needs across Europe.

Work on the patient-centred care pathway prototype moved closer to pilot testing during this period. Building on the MyPath model for patient-centred cancer care pathways, including structured use of patient-reported outcome measures, the prototype is being designed for digital, hybrid or paper-based use depending on local feasibility. A Task 6.2 pilot information meeting was held in March 2026, followed by site

mapping with responses from 23 participants across 12 sites. This will support the selection of 6–8 pilot sites and prepare later testing of pathway relevance, usability and applicability from the perspectives of patients, caregivers and healthcare professionals.

WP6 strengthened its scientific dissemination during the period. The WP6 position paper, *EU Joint Action: Integrating Palliative Care in the EU Cancer Agenda: Insights from JANE-2*, was accepted and later published in the May 2026 issue of the *Journal of Pain and Symptom Management*: [https://www.jpmsjournal.com/article/S0885-3924\(26\)00073-4/fulltext](https://www.jpmsjournal.com/article/S0885-3924(26)00073-4/fulltext).

In addition, three task-related manuscripts progressed through peer review, addressing undergraduate palliative care education across 55 European countries, oncology residency training, and indicators for palliative care integration. Together, these manuscripts support the development of European education, competence and monitoring frameworks.

WP6 also advanced collaboration with EUnetCCC through development of a Thematic Activity on Palliative Care Integration in Comprehensive Cancer Care. This gives palliative care a clearer entry point into comprehensive cancer centre standards, mutual learning, capacity-building and quality improvement. Four WP6-related abstracts were accepted for EAPC 2026, including three posters and one oral presentation, supporting visibility and dialogue with the wider European palliative care community.



WP7 NoE on Survivorship

Progress in Survivorship Care and Capacity Building

During the last six months several working group meetings were organized within Tasks 7.3 and 7.4 to further develop:

- the Integrative Survivorship Care Programme, and
- the Capacity Building Programme for healthcare professionals, patients, and caregivers.

Discussions focused on the core pillars of survivorship care and the educational resources needed to support future implementation of the programme across Europe.

Strengthening European Collaboration

In parallel, coordination meetings were held between the NoE leadership team and representatives of the EUnetCCC's Survivorship task within the framework of the European Health Policy Platform (HPP) under the newly established subgroup "Survivorship and Quality of Care".

The subgroup aims to:

- Ensure alignment between JANE-2 and EUnetCCC,
- Harmonize implementation strategies,
- Strengthen long-term sustainability perspectives

Collaboration with external organizations and stakeholders, including PanCare and PanCare4AYA, was reinforced to promote integration of survivorship initiatives across Europe.

Interactive Workshop on Governance and Patient Engagement

Within Task 7.1, an interactive workshop was conducted in February among tasks partners to discuss mainly the expected services and long-term vision of the NoE and governance optimization. Progress was also achieved in developing patient engagement strategies to better integrate patient perspectives and co-creation approaches into survivorship activities.

Barcelona Meeting: a Key Milestone

On 7–8 May 2026 the Survivorship NoE's partners gather in an in-person meeting event. The meeting brought together task leaders and more than 50 contributors.

- Day 1 focused on alignment among task leaders, discussion of major challenges, potential solutions, and definition of next steps across tasks.
- Day 2 was dedicated to updating contributors on ongoing work and engaging participants in collaborative discussions and brainstorming sessions to address identified challenges.

The meeting strengthened collaboration, shared vision, and collective commitment toward improving survivorship care across Europe.



WP8 NoE on Personalised Primary and Secondary Cancer Prevention

Advancing Personalised Cancer Prevention across Europe

The JANE-2 Network of Expertise on Personalised Primary and Secondary Cancer Prevention (WP8) is making steady progress across its ten tasks, moving from initial coordination into structured implementation. Personalised prevention is not only about identifying individual risk, it also means understanding the systems in which prevention takes place: how healthcare professionals are trained, how citizens access information, how screening policies are designed and how recommendations are translated into real-world practice.

On the scientific front, Task 8.1 is mapping existing training programmes and assessing healthcare professional needs in personalised cancer prevention. To support this work, healthcare professionals are invited to participate in the ongoing survey on education and training needs. With 136 responses received from 18 countries by early May 2026, the survey remains open and welcomes additional contributions: [survey link](#). Task 8.2 has conducted interviews with policymakers, institutions and patient representatives across Europe, finding that while personalised prevention has entered the policy vocabulary, implementation remains uneven and integration into primary care pathways is still needed. Task 8.3 is conducting a systematic review on how modifiable behaviours and environmental exposures affect cancer incidence, mortality, recurrence and survival. Tasks 8.4 and 8.5 are advancing systematic reviews on omics sciences and genetic and epigenetic risk factors, contributing directly to future personalised screening recommendations.

WP8 at the PROPHET event in Rome

In March 2026, experts and stakeholders gathered in Rome for a major event presenting the Strategic Research and Innovation Agenda and the Roadmap for Personalised Prevention, developed within the PROPHET project. Dr. Delia Nicoară, leading WP8, highlighted the network's contributions to the priorities identified in the roadmap and moderated the session on "Systems, Policy and Equity".

Annual meeting in the Azores

In May 2026, partners gathered in Ponta Delgada for the Network's annual in-person meeting, hosted by the Azores Oncology Centre. The first day brought together 35 on-site participants alongside partners joining remotely for strategic alignment, scientific exchange and operational planning. On the second day, participants visited Hospital Divino Espírito Santo and the Unidade Saúde Ilha S. Miguel Primary Care Unit, where discussions focused on primary healthcare and the integration of prevention into real-world care pathways. The meeting also featured the panel *Communicating to Prevent: Valuing Patient Co-creation in Personalised Cancer Prevention Policies*, bringing together patient representatives, healthcare professionals and policy voices to discuss how prevention policies can better reflect lived experience.



WP9 NoE on Omics Technologies


The Omics NoE's core mission is to support fast and efficient integration of omics technologies into EU healthcare systems to improve clinical decision-making in precision oncology with access for all.

We are nearing the launch of our comprehensive survey which will map the current state of omics implementation in cancer care, availability and needs regarding training and education on omics technologies, and requirements for transdisciplinary partnerships. This survey is critical for assessing the current state of the field, mapping needs and inequalities. If you are interested in participating, please let us know at JANEWP9@sciensano.be!

Our ELSI Navigator was launched

Among the objectives of our WP is to deliver adaptable and sustainable tools to support the NoE's members and stakeholders. Last month, we launched the first version of The ELSI Navigator for Omics Technologies. This modular toolkit is a crucial resource on ethical and legal aspects of omics implementation. Four modules help stakeholders navigate the complex interplay of EU regulations (e.g. GDPR, IVDR, AI Act,...) in cancer care and research. We encourage all interested parties to try it out and give us feedback so the tool can be improved in future updates. Real-world use cases will feed the toolkit, ensuring comprehensiveness, currency and relevance.

Link: <https://jane-2.eu/omics-technologies/>



Pluriannual Expert Consultations

A major pillar of the Omics NoE is our pluriannual expert consultations. The first consultation aimed to develop a future vision and roadmap for the integration of innovative omics technologies into cancer research and care. The consultation started with a survey on the topics of single-cell, spatial and integrative omics, mapping the current state of the science and experts' dream vision for these technologies. On 4 December we followed this up with an online workshop where we co-created a list of key roadblocks that need to be tackled in order to reach that dream vision. We encourage experts to reach out to us with transversal questions or issues around omics in cancer, which are internationally relevant and require a multi-stakeholder, co-creative approach. Let's leverage our community and tackle these hurdles together!



WP10 NoE on Hi-Tech Medical Resources

The NoE on High-Tech Medical Resources has entered a new phase of activity following the successful and timely submission of its first two deliverables (D10.1 in August and D10.2 in April). With these important milestones achieved, efforts are now increasingly focused on the preparation of the third deliverable (D10.3). The overall framework for this work has already been clearly defined, enabling a structured and coordinated approach across all participating domains. In close collaboration with the WP10 coordination team, domain leads are actively progressing their contributions and working toward upcoming internal deadlines to ensure continued alignment and efficiency.

This phase reflects a strong level of engagement across the network, with partners demonstrating commitment to both scientific quality and timely execution of rigorous work. Regular coordination and follow-up mechanisms are supporting this momentum, helping to identify potential bottlenecks early and maintain steady progress toward delivery.

In parallel, the NoE has advanced its dissemination efforts through the submission of the Patient Information Tool manuscript. The paper was submitted to Acta Oncologica on April 16th, 2026, and is currently under peer review as of May 5th. This represents a significant step in sharing key outputs of the network with the broader scientific and patient community.

Looking ahead, communication and dissemination activities related to this publication are being planned in collaboration with WP2. These efforts will be initiated once confirmation of publication is received, ensuring coordinated outreach and maximum visibility of the work.

Overall, the NoE and its seven highly specialised domains continue to demonstrate strong progress, with a clear transition from initial deliverables toward more advanced outputs, while maintaining active engagement in both scientific development and dissemination planning.



WP11 NoE on Adolescents and Young Adults with Cancer

We're excited to share several important milestones achieved across the Network of Expertise on Adolescents and Young Adults (AYA) with Cancer.

A major step forward has been made in shaping the survey that will underpin much of our work and map AYA cancer care organisations across Europe. Thanks to the strong collaboration between task leaders, stakeholders, and Triangulate Health, the survey is now nearing completion and dissemination. Alongside this, there has been a lot of work to strengthen country-level engagement by identifying liaison contacts across Europe.

Regarding the development of the recommendations, the first systematic search for the guideline on sexuality and affectivity has been completed and the proposed methodology for evidence analysis has been piloted. This initial exercise has allowed us to test and refine the common methodological framework that will be applied across the remaining guidelines.

The first version of a modular training curriculum for AYA cancer care has been developed, covering key topics such as clinical care, psychosocial support, survivorship, fertility, access to care, policy, and clinical research, thereby laying the foundation for a structured educational pathway in AYA oncology. In parallel, a peer-reviewed consortium paper on the educational needs and training of healthcare professionals in AYA oncology was published in the Journal of Cancer Education.

A collaboration between the NoE and the FAIR group has been launched and a manuscript advocating for better inclusion of AYA patients in clinical trials is currently being finalised. Two interactive workshops are also being prepared for September, bringing together healthcare professionals, patient advocates, and parents to share perspectives and insights.

The data extraction for the scoping review, aiming to provide a comprehensive overview of existing AYA cancer care models in the EU, has been finalised, and the synthesis phase has now started, including stakeholder consultation to gather feedback on the review findings. In parallel, progress has also been made in developing a protocol to identify and validate quality indicators for AYA cancer care through a multi-stage methodological approach, clear eligibility criteria, and a systematic screening of studies and initiatives—such as STRONG-AYA—following a completed pilot phase.

We're also pleased to welcome new partners to the network, including the European Haematology Association, further strengthening our collaborative efforts across Europe.

For the next six months, all activities are expected to be further developed, producing tangible results. Emphasis will be given on synergies with relevant Joint Actions, communication of the project's activities/achievements to targeted audiences to actively involve additional stakeholders at European level.

The next plenary meeting is scheduled to take place on October 7 -9th, 2026 in Rome, Italy. The overall progress made in the course of JANE-2's implementation since 2024 will be presented and future goals for the next two years will be discussed and agreed upon among the partners.